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Abstract
Introduction: The efficacy of many therapeutics techniques for treatment of branch retinal vein 
occlusion (BRVO) has been the subject of many investigations. The aim of the present work is to 
evaluate the transluminal Nd: YAG laser thrombolysis as a new therapeutic approach used for 
treatment of BRVO in rabbits as an experimental model. 
Methods: Four rabbits were considered as a control (n=8 eyes); occlusion of the branch retinal 
veins was performed by using a dye enhancing thrombus formation in right eyes of 10 rabbits 
(n=10 eyes). Thrombi in the retinal veins were induced by intravenous injection of rose bengal 
solution as a photosensitizer immediately before the argon laser application with a power of 
1200 mW, a spot size of 100 µm, and a duration of 20 ms. One week later, transluminal Nd: 
YAG laser thrombolysis (30 mJ, 3 pulses/4 ns) was employed to the site of occluded veins, until 
the thrombi were partially or completely shattered. The rabbits were followed up after 4 days, 
1 week and 2 weeks for slit lamp fundus examination and the treated retinas were isolated for 
histopathological examination. 
Results: Argon laser photothrombosis induced complete BRVO with some vitreous hemorrhage, 
destruction, and necrosis in the surrounding retinal layers. Moreover, one week later, Nd: YAG 
laser thrombolysis showed complete venous flow, minimal vitreous hemorrhage, reperfused 
retina, complete veins improvement. Follow up after 2 weeks revealed more improvement of 
all retinal layers. 
Conclusion: Treatment with transluminal Nd: YAG laser thrombolysis represented a novel 
therapeutic modality in BRVO.
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Introduction
Retinal vascular occlusive disease was considered as one 
of the major causes of blindness and there is marked 
argument on its clinical features, management and its 
pathogenesis.1,2 Retinal vein occlusion (RVO) is the 
commonest sight threatening vascular disease after 
diabetic retinopathy.3 RVO is an obstruction in the 
retinal veins due to thrombus formation. It was firstly 
described clinically as retinal apoplexy. 4 In addition, it 
occurs equally in both sexes especially in middle age and 
older people with systemic arterial hypertension, diabetes 
mellitus and atherosclerotic disease.5 Early treatment and 
recognition of RVO are important to avoid significant 
visual disease.6 So that research on prevention and 
treatment approaches for this sight threatening eye 
disease is needed.2
It is well known that, there are three basic types of vein 
occlusion namely, central retinal vein occlusion (CRVO); 
branch retinal vein occlusion (BRVO); and hemi-CRVO.2 
CRVO was divided into ischemic and nonischemic types 
while, BRVO is more common than CRVO and was 
divided into major BRVO and macular BRVO. Moreover, 
macular edema was present in 30% of BRVO cases.7 
Hemi-CRVO is occurred in only one half of the retina 
surface and is divided into ischemic and nonischemic 
types.6 
Compression of the retinal veins by the relatively rigid 
artery may result in endothelial damage, turbulent 
flow, thrombosis and occlusion.8 Many local anatomic, 
systemic, ocular and thrombogenic risk factors are 
associated with BRVO.9 The anatomic risk factor includes 
arteriovenous crossing, and systemic risk factors include 
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cardiovascular disease, hypertension, diabetes mellitus, 
hyperlipidemia, increased body mass index at age 20 
years, glaucoma, high levels of alpha 2-globulin and 
hematological disorders.10 In addition, ocular risk factors 
involve glaucoma and hyperopia.11 Furthermore, arterial 
hypertension and hyperviscosity are presented in the 
thrombogenic factors.12
Metabolic and systemic vascular diseases are very 
strongly connected with BRVO.13 Blood abnormalities 
play important roles in the pathogenesis of BRVO. 
Consequently, erythrocyte volume; level of fibrinogen; 
and hematocrit appeared to be substantial.14 
Recent meta-analyses of RVO and thrombophilic 
factors showed that, hyperhomocysteinemia and 
anticardiolipin antibodies play a role in the pathogenesis 
of RVO.15-20 
The main pathogenic mechanism for development 
of BRVO is arterial toughness that gives rise to venous 
compression in the common adventitial sheath.2,21-24 
According to the extent of macular damage, patients 
with BRVO may suffer from decreased vision acuity or 
vision loss. In the acute stage, the retina shows intraretinal 
hemorrhages, tortuosity and venous dilation, delayed 
venous filling, macular edema, and microvascular 
abnormalities. Recently, subretinal hemorrhage and 
serous macular detachment have been documented by 
using optical coherence tomography.25
RVO pathogenesis is still not completely 
comprehended due to a combination of three 
systemic changes: degenerative changes of the vessel 
wall (1), hemodynamic changes (venous stasis) (2), and 
blood hypercoagulability (3).15 Many therapies have 
been evaluated in the treatment of RVO such as laser 
intravitreal steroids, photocoagulation, anti-vascular 
endothelial growth factor (anti-VEGF) agents, 
hemodilution, pars plana vitrectomy, anticoagulation 
therapy and fibrinolysis. Due to its multifactorial nature, 
and no contributing treatments have been shown 
in large randomized studies seemed to be effective, 
so treatment of RVO is still a challenge.15 Thus, this 
study aimed to use transluminal Nd- YAG laser as a new 
treatment modality for experimental BRVO that induced 




Fourteen male New Zealand rabbits were obtained from 
the animal house of Research Institute of Ophthalmology, 
Giza, Egypt. The animals were kept in a standard 12 
hours of light and 12 hours of darkness cycle with free 
access to water and balanced diet. Right eyes of ten 
rabbits (weighing 3–3.5 kg) were used (n = 10 eyes) for 
creation of BRVO and eyes of four rabbits were served 
as a control. The rabbits were generally anesthetized 
using intramuscular Xyla-Ject (0.2 mL/kg) followed by 
ketamine hydrochloride (0.6 mL/kg) and benoxinate 
eye drops (0.4%) was used for local anesthesia. Animals 
pupils were dilated with 1% cyclopentolate eye drops 
(Bausch & Lomb U.K Limited). All procedures were 
directed in accordance to the principles articulated in the 
Guide for Care and Use of Laboratory Animals. They were 
subjected to experimental protocols agreed by the local 
experimental ethics committee of ophthalmic and vision 
research.
Photodynamic Therapy Induced Vein Occlusion
Occlusion of the branch retinal veins was performed 
by photodynamic therapy through dye enhanced 
photothrombosis. Thrombi were induced photochemically 
in the retinal veins using the method described previously 
by Oncel et al.26 Rose bengal (4,5,6,7-tetrachloro-2’,4’,5’,7’-
tetraiodofluorescein) was purchased from Sigma-Aldrich 
Switzerland, Buchs, Switzerland. Fifty milligrams of rose 
bengal /ml saline was injected in the middle ear vein 
immediately before argon laser photodynamic therapy 
application. Argon green laser (Vitra, France, 532 nm) 
application with a power of 1.2 W, a spot size of 100 µm, 
and duration of 20 milliseconds was performed within 5 
minutes while the rose bengal was in the venous circulation. 
Each vessel was treated at a half to one disc diameter from 
the optic disc. About 5–20 laser shoots were applied for 
each vessel until the blood flow was completely stopped in 
the vein. Occlusion was confirmed when whitening of the 
blood vessel and stasis were seen by fundus observation 
using slit lamb biomicroscopic examination. The rabbits 
were injected with intramuscular alpha chymotrypsin day 
after day for one week to reduce inflammation and eye 
tissue destruction.
Laser Thrombolysis
After 1 week of rose bengal photodynamic therapy, 
transluminal Nd: YAG laser (Optimis II, France, 1064 
nm) thrombolysis was applied to the site of occluded 
veins. A Goldman 3 mirror lens was used to focus the Nd: 
YAG laser into the venous thrombus. The laser energy 
level was operated at 30 mJ, about 12-15 pulses, spot size 
10 µm, and duration of 3 pulses/4.0 ns until the thrombus 
was completely removed. 
Fundus and Histopathological Examination of the Retina
One week after occlusion of branch retinal veins, 
fundus examination was performed and 4 rabbits were 
decapitated (n = 4 eyes) for histopathological examination. 
In addition, thrombolysis that occurred after application 
of transluminal Nd: YAG laser was confirmed in the rest 
of rabbits (n = 6 eyes) by slit lamb biomicroscopic funds 
examination. At the end of the estimated periods, the rest 
of the rabbits were sacrificed after 1 and 2 weeks (three 
rabbits each). The eyes were instantly enucleated, and 
fixed in 2.5% glutaraldehyde in phosphate buffer for half 
an hour and then the retinae were carefully removed from 
the posterior chamber of the eye for histopathological 
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examination. The retinae specimens were dissected 
into small pieces and instantly fixed in 2.5% phosphate 
buffered glutaraldehyde (pH 7.4) at 4°C for 6 hours. The 
specimens were fixed in 1% osmium tetra-oxide for 30 
minutes, dehydrated in an ascending grade of ethanol and 
then embedded in araldite CY212 mixtures. Semithin 
sections were cut (1 µm) and stained with toluidine blue 
for light microscope examination.
Results
Fundus Examination
The slit lamp biomicroscopic fundus examination for 
control rabbits showed normal retina and vascular complex 
(Figure 1A). Argon laser was applied after injection of 
intravenous rose bengal to induce BRVOs in ten rabbit’s 
eyes (Figure 1B and 1C). Following the photothrombosis, 
the area of irradiated retinal vein was narrow with 
complete BRVOs. Four days later, fundus examination 
revealed vitreous hemorrhage, venous tortuosity, blurred 
disc edge and hemorrhage around disc (Figure 1D). One 
week after photothrombosis, slit lamp biomicroscopic 
fundus examination showed disappearance of vitreous 
hemorrhage (Figure 1C). BRVO in the right eye of all 
rabbits were treated by Nd: YAG laser till thrombolysis 
occurred and flow of blood stream was attained (Figure 
2A). In some rabbits, injury to venous wall and stream 
of blood flow occurred with improvement of the pale 
colored retina (Figure 2B). Follow up after one week using 
slit lamp biomicroscopic fundus examination revealed 
complete venous flow, minimal vitreous hemorrhage, 
and dry pale retina (Figure 2C). After 2 weeks, fundus 
examination showed normal retina and complete veins 
improvement (Figure 2D).
Histopathological Examination
The histopathological section for the control retina of 
albino rabbit showed retinal pigment epithelium (PE), 
photoreceptor layer (Ph), outer limiting membrane 
(OLM), outer nuclear layer (ONL), outer plexiform layer 
(OPL), inner nuclear layer (INL), inner plexiform layer 
(IPL), ganglion cell layer (GCL), nerve fiber layer (NFL) 
and inner limiting membrane (ILM), with no significant 
microscopic alteration in all retina’s layers (Figure 3A). 
Histological examination after one week of rose bengal 
photodynamic therapy induced BRVO (Figure 3B) 
showed necrosis and destruction in the surrounding 
retina, decreasing in thickness and dissolution of the 
photoreceptor layer with pyknosis of the nuclei of the outer 
nuclear layer. The inner retinal layers lost its architecture 
and infiltrated with chronic inflammatory cells. In 
addition, the capillary of the ganglion cell layer had thick 
wall and the plexiform layer lost the reticular appearance. 
A B C D E
Figure 1. (A) Control rabbit′s retina showed normal retina and vascular complex, (B) the location of the applied argon laser, (C) complete 
branch vein occlusion, (D) hemorrhage around the disc and in the vitreous gel after 4 days of vein occlusion, (E) resolved vitreous and 
venous thrombosis after 1 week.
Figure 2. (A) Flow of Blood Stream After Nd: YAG Thrombolysis, (B) Injured Venous Wall With Reflow of Blood Stream, (C) Complete 
Venous Flow, Minimal Vitreous Hemorrhage and Dry Retina After 1 Week, (D) Normal Retina After 1 Weeks.
A B C D
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All these changes in the retinal layer showed slight 
improvement after 1 week of treatment with transluminal 
Nd: YAG laser as shown in Figure 3C especially in the 
photoreceptor layer, ganglion cells layer and outer 
nuclear layer. After 2 weeks, the histopathological 
sections showed more noticeable improvement in the 
inner segment of photoreceptor layer, the ganglion cell 




Retinal vein occlusion disease is a common cause of 
visual loss particularly in the elderly with history of 
hypertension and arteriosclerotic vascular disease. The 
occlusion is assumed to be caused by formation of venous 
thrombosis with different degrees of obstruction to venous 
outflow. These usually take the form of varying degrees of 
ischemia, cystoid macular edema, preretinal fibrosis, and 
pigmentary dispersion. The existing therapeutic options 
for the treatment of RVO are nonspecific because they 
fail to report the basic pathological process causing the 
obstruction in the retinal vein and are limited in their 
effectiveness. Unfortunately, now there is no means of 
treatment that is safe and can avoid the progression of a 
partial retinal vein occlusion to the complete form. 
The previous treatments for complete occlusions by 
laser photocoagulation of the ischemic area aimed to 
prevent neovascular problems rather than the restoration 
of vision.27 Numerous therapeutic approaches have 
been tried in the treatment of central retinal venous 
occlusion, most with limited or no success and were 
not promising curative treatments to occlusive diseases. 
Therapies such as x-rays, vitamins, ocular hypotensive 
agents, anticoagulants and corticosteroids have also 
proved to be ineffective.28,29 Topical pilocarpine and 
cholesterol lowering agents were used in the past with 
no scientific basis and were ineffective.30 Thrombolytic 
drugs such as streptokinase have been associated with an 
unacceptable severe side effects.31 In addition, Green et al 
have recognized that the chronic inflammatory infiltrate 
found in the area of the thrombosis in the central retinal 
vein was a consequence of the occlusion rather than 
the cause.32 Current management is depend on some 
recommendations and new surgical techniques.33,34 The 
applied technique of vitrectomy and artery vein (AV) 
sheathotomy to separate the artery and vein at the AV 
crossing induced improvement in visual acuity but it 
may be accompanied with macular edema, macular 
hemorrhage, and retinal perfusion.35 Restrictions include 
difficulty in separating the vessels, retinal detachment, 
hemorrhage and visual field defects. Clot selective agents 
such as tissue plasminogen activators, offer a theoretical 
advantage but the results of clinical trials remain to be 
seen.26 Isovolaemic hemodilution has been shown to 
improve retinal microcirculation with no effect on the 
extent of obstruction to venous outflow.36 
More recently, vitrectomy with separation of the 
posterior hyaloid with or without internal limiting 
membrane peeling was used for the treatment of macular 
edema associated with BRVO.37,38 This procedure 
was shown to decrease macular edema and improve 
visual acuity in some patients. Moreover, treatment of 
macular edema with intravitreal triamcinolone and focal 
photocoagulation showed a limited success.39 Previously, 
it was shown that, the vascular endothelial growth factor 
protein (VEGF) was significantly increased after BRVO. 
Therefore, the use of anti-VEGF therapy has been 
introduced for treatment of BRVO-induced macular 
edema.40 None of these previous forms of treatment are 
widely used due to the lack of effectivity, deleterious side 
effects and no permanent improvement in the retinal 
circulation was attained. 
 In this research, occlusion of the BRV was performed 
successfully by photodynamic therapy using dye enhanced 
photothrombosis to induce thrombi in the branch retinal 
veins.26,41 Argon laser causing photosensitization of the 
rose bengal dye until the blood flow was completely 
stopped in the vein. Fundus examination revealed vitreous 
hemorrhage, venous tortuosity, blurred disc edge and 
hemorrhage around disc with complete vein occlusion. 
A B C D
Figure 3. (A) Light micrograph of control rabbit’s retina, (B) one week after BRVO by argon laser, the photoreceptor layer was dissolute; there 
were pyknotic nuclei in the outer nuclear layer. The inner retinal layers lost their architecture and infiltrated with chronic inflammatory cell, 
(C) One Week After Nd:YAG laser thrombolysis showed slight improvement in all retinal layers, (D) Two weeks after Nd:YAG laser showed 
nearly improved retinal layers (Toluidine blue, scale bar: 50 µm)
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The retinal vein obstruction was owing to formation 
of an intraluminal thrombus. This obstruction blocks 
venous outflow, producing a complete obstruction and 
inner retinal hypoxia. Histopathological sections of the 
retinal layers after one week of photothrombosis revealed 
changes in the photoreceptor layer, the outer nuclear 
layer, the inner retinal layers, destruction and necrosis in 
the surrounding retina (Figure 3B). Additionally, these 
lesions to retinal layer had similar appearance to those 
described by Chidlow et al.42 Photodynamic therapy 
would cause collateral lesion via expanding and collapsing 
vapor bubbles that affected neighboring photoreceptors 
and the other retinal layer.42 
The use of thrombolysis for the treatment of BRVO was 
the subject of intense investigation.
The Nd:YAG laser (1064 nm), in the infrared range has 
a precise laser focus spot with small penetrating power 
causing photodisruption of a thrombus within an 
occluded BRV. This rapidly increases the temperature 
of the thrombus between 100 and 305°C, and partially 
or completely dislodge the thrombus.43 This, in turn, 
generates both hydrodynamic and acoustic shock 
waves. The acoustic shock waves are responsible for the 
desired cleavage of the thrombus, and cavitation bubble 
formation without harming the venous wall.43 Fundus 
examination showed restoration of retinal blood flow 
with improvement of the pale colored retina. One week 
after Nd: YAG laser thrombolysis, histopathological 
sections, showed slight recovery of retinal layers but rapid 
perfusion and dramatic improvement of the retina could 
be accomplished after 2 weeks without collateral damage 
occurring. 
Conclusion
This research investigates the possibility of creating 
BRVOs in rabbits’ eyes at the site of application of argon 
laser photothrombosis and targeting the formed thrombus 
by transluminal Nd: YAG laser thrombolysis as a recent 
modality in treatment of BRVO with no significant 
complications. Long term studies are being conducted 
in order to evaluate the effect of transluminal Nd: YAG 
laser thrombolysis on the retinal veins and to monitor the 
possible development of complications.
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